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Abstract
Background Metastatic Merkel cell carcinoma (mMCC) is a rare and aggressive skin cancer. Until recently, there were no licensed 
treatment options for patients with mMCC, and prognosis was poor. A cost-effectiveness analysis was conducted for avelumab, a 
newly available treatment option for mMCC, versus standard care (SC), from a UK National Health Service perspective.
Methods A partitioned survival model was developed to assess the lifetime costs and effects of avelumab versus SC. Data 
from the JAVELIN Merkel 200 trial (NCT02155647) were used to inform estimates of quality-adjusted life-years (QALYs). 
Unit costs and associated frequencies of use were informed by published literature and clinical expert opinion. Results were 
presented as incremental cost-effectiveness ratios (ICERs, i.e. the cost per QALY gained) for treatment-experienced (TE) 
and treatment-naïve (TN) patients. Uncertainty was explored through a range of sensitivity analyses.
Results Discounting costs and QALYs at 3.5% per annum, avelumab was associated with ICERs of £35,274 (TE)/£39,178 
(TN) per QALY gained. Probabilistic sensitivity analysis results demonstrated that avelumab was associated with an 88.3% 
(TE)/69.3% (TN) probability of being cost effective at a willingness-to-pay threshold for end-of-life treatments of £50,000 
per QALY gained. Results were most sensitive to alternative survival extrapolations and dosing assumptions.
Conclusions The analysis results suggest that avelumab is likely to be a cost-effective treatment option for UK mMCC 
patients. The results for TN patients are subject to some uncertainty, and a confirmatory analysis will be conducted with 
more mature data.
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Key Points for Decision Makers 
Treatment options for patients with metastatic Mer-
kel cell carcinoma (mMCC) are severely limited, and 
survival for patients with mMCC is poor with existing, 
unlicensed palliative chemotherapy regimens and best 
supportive care.
Avelumab may provide a cost-effective option for 
treatment-experienced mMCC patients and, while data 
are still maturing, demonstrates promising outcomes in 
treatment-naïve mMCC patients.
1 Introduction
Merkel cell carcinoma (MCC) is a rare, aggressive skin 
cancer [1–3]. It is most common in fair-skinned patients 
> 65 years of age on sun-exposed skin [3, 4]. From 1999 
to 2008, 1515 cases of MCC were captured by the National 
Cancer Data Repository in England, with a currently esti-
mated incidence rate of 0.2–0.4 cases per 100,000 people 
per year in Europe [4, 5]. MCC is associated with a high 
risk of local recurrence and distant metastases and is often 
asymptomatic on presentation, delaying diagnosis [5, 6]. 
The majority of MCC patients present with local or nodal 
disease, however an estimated 5–12% of patients present 
with metastatic disease [6, 7], and approximately 37% of 
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patients will develop metastases over the course of their 
disease [8–10].
Until recently, no treatment options with regulatory 
approval existed for patients with metastatic MCC (mMCC). 
Consequently, patients were typically treated with unli-
censed standard care (SC): a combination of palliative chem-
otherapy, radiotherapy and best supportive care (BSC) [5, 
11]. Although these treatments can induce clinically mean-
ingful responses, responses are generally short-lived. Given 
the lack of an effective and well-tolerated treatment option, 
mMCC was associated with poor prognosis. In observational 
studies, estimated median survival following SC treatment 
is between 4 and 13 months [8, 9, 12, 13].
Avelumab (tradename:  Bavencio®) is a human immuno-
globulin (Ig) G1 monoclonal antibody that targets cancer 
cells through the inhibition of the immune checkpoint pro-
tein programmed death-ligand 1 (PD-L1) [14]. The efficacy 
and safety of avelumab was studied in the pivotal phase II, 
single-arm JAVELIN Merkel 200 trial. Data from this trial 
are from two distinct cohorts: Part A, 88 treatment-experi-
enced (TE) patients (patients who have received at least one 
prior line of systemic therapy for mMCC); and Part B, with 
a planned enrolment of 112 treatment-naïve (TN) patients [7, 
15]. The findings from JAVELIN Merkel 200 demonstrate 
that avelumab provides an effective and well-tolerated treat-
ment for patients with mMCC [7, 16].
In 2017, the National Institute for Health and Care 
Excellence (NICE) initiated its assessment of avelumab for 
mMCC (TA517) with the objective of appraising the clini-
cal and cost effectiveness of avelumab within its marketing 
authorisation [17]. NICE published its final guidance for 
TA517 in March 2018, recommending avelumab for routine 
use in the National Health Service (NHS) for TE patients, 
and for use within the Cancer Drugs Fund for TN patients, 
based on preliminary data [18].
The cost-effectiveness analysis (CEA) submitted for 
TA517 represents the first CEA in MCC appraised by NICE. 
Since publication, additional data have been made available 
from the JAVELIN Merkel 200 trial [19]. These data permit 
an update of the survival and treatment duration projections 
included within the CEA, acknowledged as key drivers of 
avelumab’s estimated cost effectiveness during TA517. In 
this study, we provide a description of the economic model 
and associated inputs used to inform TA517, and update 
the results with the latest available data from the JAVELIN 
Merkel 200 trial.
2  Methods
2.1  Model Overview
A three-state, partitioned survival model was constructed 
to assess the cost effectiveness of avelumab versus SC. 
This model structure is commonly used to assess the cost 
effectiveness of end-stage cancer interventions, including 
other immune checkpoint inhibitors [20–23]. Health states 
considered in the model to inform estimates of costs and 
health-related quality of life (HRQL) were based on progres-
sion status (i.e. pre- or post-progression) and/or the time 
until death (categorised by > 100, 30–100, or < 30 days 
until death). Transitions between progression-based health 
states were informed by extrapolated overall survival (OS) 
and progression-free survival (PFS) curves, and the time to 
death categorisation was estimated using OS data alone. The 
model structure is presented in Fig. 1.
The outcomes of interest from the model are the dif-
ferences in modelled costs, life-years (LYs) and quality-
adjusted life-years (QALYs) between treatment arms. Deter-
mination of the differences in costs and QALYs across the 
treatment arms allowed for the calculation of the cost per 
QALY gained, also known as the incremental cost-effec-
tiveness ratio (ICER).
Fig. 1  Model schematic. OS 
overall survival, PFS progres-
sion-free survival
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Aligned with NICE guidance, costs and QALYs were 
discounted at an annual rate of 3.5% and considered from a 
UK NHS and Personal Social Services perspective [24]. A 
lifetime horizon (40 years) was adopted, with a cycle length 
of 7 days. The time horizon was long enough to ensure that 
nearly 100% of (primarily elderly) patients had died by the 
end of the model, while the cycle length of 7 days was short 
enough to accurately model costs and outcomes. A cost year 
of 2015–2016 was used to inform the analysis, based on the 
latest available cost data at the time of submission to NICE.
The clinical and cost model parameters are provided in 
Appendix Table 3, with further details provided in Sects. 2.2 
and 2.3, respectively. The validation exercises undertaken 
for the clinical model parameters are discussed in Sect. 2.4, 
and the analyses undertaken are discussed in Sect. 2.5.
2.2  Clinical Model Parameters
2.2.1  Comparator Treatments
As avelumab is the only treatment option currently 
licensed for patients with mMCC, clinical expert opinion 
was sought to establish the component SC treatments for 
mMCC patients in the absence of avelumab. An overview 
of how clinical expert opinion was obtained is discussed in 
Sect. 2.4.
In the UK, SC for mMCC patients is composed of pallia-
tive chemotherapy, radiotherapy and BSC. Clinical expert 
opinion suggested that all chemotherapy regimens offered 
to patients are expected to be similarly efficacious, therefore 
the CEA assumed no difference in chemotherapy regimen 
efficacy. Furthermore, as no studies of outcomes for patients 
treated with BSC or individual chemotherapy regimens were 
identified, we assumed equivalent efficacy of all palliative 
chemotherapy regimens and BSC (considered appropriate by 
clinical experts, particularly in the TE setting).
In practice, the majority of TE patients (95%) are 
expected to receive BSC as opposed to a further line of 
chemotherapy, whereas for TN patients approximately 50% 
are expected to be treated with chemotherapy, with the 
remainder treated with BSC. The chemotherapy regimens 
offered to patients with mMCC are largely platinum-based, 
therefore we assumed 50% of patients receiving chemother-
apy are treated with carboplatin + etoposide and the remain-
ing 50% are treated with cisplatin + etoposide (informed by 
clinical experts, owing to a lack of robust market share data 
for UK patients treated in practice) [25].
The results of this CEA considered three separate com-
parator treatment arms: (1) BSC; (2) chemotherapy; and (3) 
SC—a blend of BSC and chemotherapy aligned with clini-
cal expert opinion. Pairwise comparisons were provided for 
each comparator versus avelumab. However, the base-case 
comparison of avelumab versus SC was considered to be the 
most relevant to current practice.
2.2.2  Survival Outcomes for Comparator Treatments
JAVELIN Merkel 200 is a single-arm trial of avelumab for 
patients with mMCC. Therefore, to inform the CEA, data 
regarding the outcomes for patients treated with palliative 
chemotherapy or BSC were sought. Individual-level data 
were available from three observational studies (n  = 20 TE 
US patients; n  = 67 US TN patients; and n  = 34 TE Euro-
pean patients) [26–28]. Aggregate-level data were reported 
in other published sources [8, 9, 12, 13, 29, 30].
Owing to similarities in patient characteristics and the 
designs of JAVELIN Merkel 200 and the observational stud-
ies (each conducted by Merck KGaA, Darmstadt, Germany), 
as well as the availability of individual-level data, the three 
observational studies were used to inform the OS and PFS 
estimates for both palliative chemotherapy and BSC. Data 
for TE patients were reported in two of the three studies and 
were naïvely pooled (pooled without adjustment for baseline 
characteristics) ahead of fitting parametric survival models 
(PSMs). Naïve pooling was undertaken as no explanatory 
variables (beyond whether a patient had been previously 
treated) could be identified using either multivariate or uni-
variate regression, or visual inspection of Kaplan–Meier 
curves. Details of the analyses undertaken (and data used) 
have been reported by Hatswell et al. and within the NICE 
single technology appraisal (STA) documentation [31–33].
The Kaplan–Meier curves for the OS and PFS of TE and 
TN patients receiving palliative chemotherapy are provided 
in Fig. 2. Technical guidance from the NICE Decision Sup-
port Unit (DSU) [Technical Support Document (TSD) 14] 
[34] was followed when fitting PSMs. PSMs were selected 
based on their visual fit, statistical fit, and plausibility of 
their extrapolations in comparison to available external data. 
Gompertz and Weibull models were selected to model OS 
and PFS for TE patients, respectively, while log-logistic 
models were selected to model both OS and PFS for TN 
patients.
2.2.3  Survival Outcomes for Avelumab
OS and PFS data for patients treated with avelumab are 
available from the JAVELIN Merkel 200 trial. The mini-
mum follow-up for Part A was 18 months, however data 
from Part B are less mature (39 of the planned 112 patients 
enrolled; minimum, maximum and median follow-up of 0.3, 
11.3 and 5.1 months, respectively). Therefore, the survival 
extrapolations considered for both cohorts use data from Part 
A of the trial [19].
The Kaplan–Meier curves for the OS and PFS of TE 
and TN patients receiving avelumab are provided in Fig. 3. 
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Owing to the plateau observed in the PFS curve for TE 
patients from approximately 6 months, as well as the emer-
gent plateau in the OS curve, flexible PSMs were explored 
to inform the estimation of OS and PFS in the longer term 
for TE patients treated with avelumab. Royston and Parmar 
natural cubic spline-based models were applied for the OS 
and PFS of patients treated with avelumab in the CEA base 
case [35]. The spline-based models exhibit greater sensitiv-
ity compared with traditional PSMs, to reflect the changing 
hazards in the observed survival in JAVELIN Merkel 200.
For TN patients, data were considered too immature 
to extrapolate into the longer term, therefore two distinct 
approaches were taken to model survival-based outcomes for 
this cohort: (1) use expert-elicited hazard ratios (HRs) via a 
Fig. 2  Survival outcomes for 
patients treated with palliative 
chemotherapy and best support-
ive care. 1L treatment-naïve, 
2L+ treatment-experienced, OS 
overall survival, PFS progres-
sion-free survival
Fig. 3  Survival outcomes for 
patients treated with avelumab. 
Data-cut for Part A: 26 Septem-
ber 2017; data-cut for Part B: 
24 March 2017. 1L treatment-
naïve, 2L+ treatment-experi-
enced, OS overall survival, PFS 
progression-free survival
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face-to-face interview to adjust the OS (0.8) and PFS (1.0) 
extrapolations for TE patients based on the expected increase 
in average survival for TN patients versus TE patients; or (2) 
use a curve fitted to the TN data until no longer considered 
valid, and then consider the extrapolation for TE patients. In 
the model base case, we used approach 1 as this method syn-
thesises mature data for TE patients in the longer term with 
clinical expert opinion regarding the expected improvement 
in OS in the shorter term, instead of relying on the maturing 
Part B data alone. However, approach 2 was considered as 
a scenario analysis.
2.2.4  Adverse Events
The CEA also included the cost and/or health impacts of 
any treatment-emergent adverse events (AEs). AE rates for 
patients treated with palliative chemotherapy were sourced 
from a systematic literature review, where one study was 
used for each chemotherapy regimen considered (in small-
cell lung cancer [SCLC], as no evidence was available for 
MCC and clinical expert opinion considered SCLC a reason-
able proxy in the absence of data for MCC) [25, 36, 37]. For 
unreported AEs for the palliative chemotherapy regimens, a 
rate of 0% was applied conservatively.
For avelumab patients, AE rates were taken from Part 
A of the JAVELIN Merkel 200 trial (due to the maturity of 
data from this cohort) and assumed to apply for both TE and 
TN patients. Overall, avelumab was well tolerated compared 
with chemotherapy regimens, which, in general, are associ-
ated with high rates of haematological abnormalities and 
hair loss [7, 36, 37]. The most commonly reported AEs for 
avelumab and chemotherapy were lymphopenia (grade ≥ 3, 
2.27%) and neutropenia (grade ≥ 3, 45.49%), respectively 
[7, 36, 37].
2.2.5  Health‑Related Quality of Life
HRQL was assessed for patients in JAVELIN Merkel 200 at 
baseline, week 7, every 6 weeks thereafter, and at the end-
of-treatment visit via the EQ-5D-5L® questionnaire [38, 39]. 
Data from Part A of the JAVELIN Merkel 200 trial were 
analysed to inform the CEA for both cohorts of patients.
Two approaches to incorporating HRQL data were con-
sidered in the model: (1) a time-to-death approach using the 
‘crosswalk’ algorithm reported by van Hout et al. to convert 
EQ-5D-5L to EQ-5D-3L® values; and (2) a progression-
based approach using the EQ-5D-5L value set reported 
by Devlin et al. [31, 33, 39–42]. The CEA base case was 
informed by time-to-death utilities used in the NICE STA, 
and the progression-based approach was considered as a sce-
nario analysis. The time-to-death approach was used in the 
NICE STA as few measurements of EQ-5D-5L were avail-
able for patients beyond progression in JAVELIN Merkel 
200. Furthermore, measurements were collected solely for 
patients who were fit enough to continue treatment after 
progression. Therefore, the use of progression-based utili-
ties may overestimate the HRQL of progressed patients in 
clinical practice.
Disutilities for AEs were also included for patients 
receiving active treatment (i.e. avelumab or palliative 
chemotherapy), with disutility values taken from published 
sources [43–45]. Disutilities attributable to AEs are applied 
as a weekly QALY decrement to those patients receiving 
treatment.
2.3  Cost Model Parameters
2.3.1  Treatment Costs
Avelumab is available in a 200 mg/10 mL vial priced at 
£768.00 [46]. Per its summary of product characteristics, 
avelumab is administered as an intravenous infusion once 
every 2 weeks at a target dose of 10 mg/kg [14]. To deter-
mine the average cost per administration, the distribution of 
patient weight was determined from patients in Part A of the 
JAVELIN Merkel 200 trial, and the relative dose intensity 
of 95.4% observed within the trial was accounted for [47].
After fitting a log-normal distribution to the weight data, 
the proportion of patients requiring each number of vials per 
administration was determined and costed within the model. 
This method ensures drug wastage is included within the 
avelumab costing (e.g. a 79 kg patient requires 790 mg and 
would therefore incur the cost of four vials [10 mg wastage], 
whereas an 81 kg patient requires 810 mg and would there-
fore incur the cost of five vials [190 mg wastage]). This tech-
nique for costing weight-based treatments is often termed 
the ‘method of moments’ [48].
In the model base case, the ‘method of moments’ 
approach was applied for European patients as this method 
costs all patients per the exact licensed dose and considers 
the group of patients expected to be most similar to those 
treated in NHS practice. This results in an average of 4.25 
vials per administration, costing £3261.04. A scenario 
analysis was considered using the published NHS England 
National Dose Banding Table (NDBT) for avelumab [49].
Time on treatment (ToT) data were taken from Part A 
of the JAVELIN Merkel 200 trial to inform the duration of 
treatment. Clinical expert opinion suggested that based on 
the precedent set by other immune checkpoint inhibitors, the 
majority of patients (i.e. approximately 95% of those initiat-
ing treatment) would not be expected to receive avelumab 
after 2 years, and all patients are likely to have discontin-
ued by 5 years. A Weibull PSM provided the best fit to the 
observed data and aligned with the aforementioned clinical 
expert opinion. For TN patients, an HR of 1.0 was used to 
inform the model base case (per clinical expert opinion); 
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however, in a scenario analysis, the immature TN data were 
used as the basis for extrapolation. Like TE patients, cli-
nicians advised that at 2 years, only 5% of patients were 
assumed to continue treatment, and by 5 years all patients 
were assumed to have discontinued.
Carboplatin + etoposide and cisplatin + etoposide were 
administered according to their use in previous studies of 
SCLC [36, 37]. During validation through consultation 
with mMCC clinical experts, it was suggested that for the 
carboplatin + etoposide regimen, patients could take an oral 
dose of etoposide 200 mg/m2 for days 2 and 3 of a 3-week 
cycle [25, 36, 37]. This regimen was assumed in the base-
case CEA. Both chemotherapy regimens were assumed 
to be administered for a maximum of six treatment cycles 
(18 weeks) unless a patient progressed or died.
Unit costs for the chemotherapy regimens were sourced 
from the British National Formulary (BNF) for branded 
medicines and the NHS electronic market information tool 
(eMIT) for generic medicines associated with published 
NHS discounts. Using a clinically validated estimate of the 
relative dose intensity for palliative chemotherapy (66.7%) 
and an assumed 50:50 split across both regimens, a weekly 
cost of £12.43 was applied in the CEA for the cost of chemo-
therapy treatment.
Treatments costed within the model are administered 
either as an intravenous or oral treatment. An intravenous 
administration cost of £199, taken from the NHS reference 
costs database, was applied per intravenous administration, 
whereas the cost of oral medication administration was 
assumed to be zero [50].
2.3.2  Medical Resource Use
Patients are expected to incur a range of monitoring costs, 
including general practitioner (GP) visits, computed tomog-
raphy (CT) scans, and routine blood and organ function tests. 
Costs of monitoring and resource utilisation were taken from 
the NHS reference costs database and the Unit Costs for 
Health and Social Care [50, 51]. Frequencies of monitoring 
visits and tests were procured from mMCC clinical experts.
In addition to the costs of monitoring, some patients 
may receive palliative radiotherapy for symptom manage-
ment. Consultation with mMCC clinical experts suggested 
that radiation therapy is received by approximately 75% of 
patients, involving approximately one to five fractions, and 
administered one to two times in total. The cost per fraction 
of radiotherapy treatment was taken from the NHS reference 
costs database [50].
Costs associated with AE resolution were identified 
from published literature sources and were inflated using 
the Hospital and Community Health Services (HCHS) 
index reported in the Unit Costs for Health and Social Care 
[51–53].
As no data were identified regarding the costs associated 
with end-of-life care for mMCC patients, average costs for 
health and social care relating to end-of-life care for terminal 
cancer patients were taken from the study by Round et al. 
[54]. The costs reported in that study were inflated using the 
aforementioned HCHS index [51]. The total cost for end-of-
life care was £7019.12, applied within the CEA as a lump 
sum upon death.
2.4  Clinical and External Validation
Inputs considered within the CEA were validated by mMCC 
clinical experts through an advisory board and follow-up 
one-to-one consultations [25]. Consultation with clinical 
experts led to the inclusion of radiotherapy costs for symp-
tom management and confirmation of the standard chemo-
therapy regimens considered (platinum-based chemother-
apy), as well as the relative use of carboplatin and cisplatin 
(cisplatin is used for patients unable to tolerate carboplatin). 
The choice of model structure, survival extrapolation tech-
niques and approaches to incorporating HRQL data were 
also validated by both clinical and economic experts.
The submitted CEA, as well as later updates, were cri-
tiqued by an independent Evidence Review Group (ERG) 
during NICE TA517 [31]. The ERG’s comments were 
implemented within the revised model, including the use of 
a Weibull curve for the avelumab ToT curve, inflation of end-
of-life care costs, and the appropriate frequencies of medical 
resource use [55]. Finally, the CEA was subject to several 
independent quality control checks throughout development 
to check for modelling errors and/or implausible results by 
stress testing various model inputs and assumptions.
2.5  Analysis
The base case considered the results of a deterministic CEA. 
Probabilistic sensitivity analysis (PSA) was conducted to 
ascertain the probability of avelumab being a cost-effective 
treatment option for mMCC patients, at the willingness-to-
pay threshold (λ) of £50,000 considered cost effective for 
end-of-life treatments [56]. Deterministic scenario analy-
sis (DSA) was also undertaken to assess the sensitivity of 
the base-case results to various structural and/or alternative 
assumptions. The scenarios considered alternative assump-
tions regarding survival extrapolation methods, use of TE 
data to inform TN patient outcomes, application of HRQL 
data, and dosing.
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3  Results
3.1  Base‑Case Results
The base-case CEA results are provided in Table 1. At a 
λ of £50,000 per QALY gained, avelumab was shown to 
be a cost-effective treatment option for TE and TN mMCC 
patients. The base-case ICER was £35,274 for the TE popu-
lation and £39,178 for the TN population. Avelumab was 
estimated to provide 45 months extension to OS for TE 
patients and 43 months extension to OS for TN patients 
compared with SC. Furthermore, an increase of 2.24 and 
1.96 QALYs was predicted for avelumab versus SC for the 
TE and TN populations, respectively.
3.2  Probabilistic Sensitivity Analysis
PSA was performed by running 2000 probabilistic iterations 
for each modelled population of mMCC patients. The results 
of the PSA (presented in Table 2 and the Appendix Table 3) 
demonstrated that avelumab was associated with an 88.3% 
(TE)/69.3% (TN) probability of being cost effective at a λ 
of £50,000 per QALY gained versus SC (Figs. 4, 5, 6, 7).
3.3  Deterministic Sensitivity Analysis
The DSA undertaken considered alternative assumptions 
regarding the application of HRQL data, the dosing of ave-
lumab and the use of data to inform survival extrapolations 
for TN patients. The results of the scenarios are discussed 
in turn below.
Table 1  Base-case deterministic 
pairwise cost-effectiveness 
results
BSC best supportive care, ICER incremental cost-effectiveness ratio, LYs life-years, mMCC metastatic 
Merkel cell carcinoma, QALYs quality-adjusted life-years, SC standard care, TE treatment-experienced, TN 
treatment-naïve
Treatment Total Incremental (vs. avelumab) ICER (£)
Costs (£) LYs QALYs Costs (£) LYs QALYs
TE mMCC
Chemotherapy 9834 0.41 0.30 78,395 3.74 2.30 34,113
SC 7584 0.41 0.31 80,646 3.74 2.29 35,274
BSC 7465 0.41 0.31 80,764 3.74 2.29 35,335
Avelumab 88,229 4.15 2.60
TN mMCC
Chemotherapy 10,607 1.94 1.34 77,292 3.56 2.02 38,205
SC 8918 1.94 1.35 78,981 3.56 2.02 39,178
BSC 7229 1.94 1.36 80,669 3.56 2.01 40,158
Avelumab 87,899 5.50 3.37
Table 2  Base-case probabilistic 
cost-effectiveness results
BSC best supportive care, ICER incremental cost-effectiveness ratio, LYs life-years, mMCC metastatic 
Merkel cell carcinoma, QALYs quality-adjusted life-years, SC standard care, TE treatment-experienced, TN 
treatment-naïve
Pairwise cost-effectiveness results
Treatment Total Incremental (vs. avelumab) ICER (£)
Costs (£) LYs QALYs Costs (£) LYs QALYs
TE mMCC
Chemotherapy 9838 0.41 0.30 80,143 3.84 2.35 34,076
SC 7591 0.41 0.31 82,390 3.84 2.34 35,208
BSC 7473 0.41 0.31 82,508 3.84 2.34 35,268
Avelumab 89,981 4.26 2.65
TN mMCC
Chemotherapy 10,622 1.95 1.35 80,573 3.64 2.07 38,986
SC 8929 1.95 1.36 82,266 3.64 2.06 39,943
BSC 7236 1.95 1.37 83,959 3.64 2.05 40,907
Avelumab 91,194 5.60 3.42
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Table 3  Model parameters
Parameter Value Lower 95% 
CI
Upper 95% CI Distribution Source or justification
Discount rate, costs 3.50% NA NA Varied in scenario analysis NICE reference case [59]
Discount rate, QALYs 3.50% NA NA Varied in scenario analysis
Discount rate, LYs 0.00% NA NA Varied in scenario analysis
Model cycle length 1 week NA NA Not varied Structural assumption
Model time horizon 40 years NA NA Not varied NICE reference case [59]
HR: improvement in OS for avelumab (TN 
vs. TE)
0.800 0.655 0.968 Log-normal Assumptions validated by 
clinical expert opinion
HR: improvement in PFS for avelumab (TN 
vs. TE)
1.000 0.818 1.210 Log-normal
RDI: avelumab 95.43% 93.59% 97.27% Normal JAVELIN Merkel 200 [7]
RDI: chemotherapy 66.67% 53.60% 79.73% Normal Clinical validation
Utility, progression-free, (-5L) 0.827 0.783 0.867 Beta Kaufman et al. [39]
Utility, post-progression (-5L) 0.742 0.690 0.790 Beta
Utility, > 100 days to death (-3L) 0.774 0.734 0.813 Beta NICE TA517 [55]
Utility, 30–100 days to death (-3L) − 0.020 0.000 − 0.108 Beta
Utility, < 30 days to death (-3L) − 0.066 − 0.020 − 0.138 Beta
Administration cost, IV drugs £199.00 £198.81 £199.19 Normal NHS reference costs 15–16 
[50], PSSRU 2016 [51]Cost, GP visit £36.00 £28.94 £43.06 Normal
Cost, CT scan £120.99 £120.95 £121.03 Normal
Cost, FBC £3.00 £3.00 £3.00 Normal
Cost, LFT £1.00 £0.80 £1.20 Normal
Cost, RFT £1.00 £0.80 £1.20 Normal
Cost, TFT £1.00 £0.80 £1.20 Normal
Cost, radiotherapy £126.60 £126.58 £126.62 Normal
Cost, EoL, health care £4867.53 £3913.51 £5821.55 Normal Round et al. [54]
Cost, EoL, social care £2151.59 £1729.89 £2573.29 Normal
MRU frequency, GP visit, avelumab, PF 0.250 0.201 0.299 Normal Assumptions validated by 
clinical expert opinionMRU frequency, CT scan, avelumab, PF 0.077 0.062 0.092 Normal
MRU frequency, FBC, avelumab, PF 0.500 0.402 0.598 Normal
MRU frequency, LFT, avelumab, PF 0.500 0.402 0.598 Normal
MRU frequency, RFT, avelumab, PF 0.500 0.402 0.598 Normal
MRU frequency, TFT, avelumab, PF 0.500 0.402 0.598 Normal
MRU frequency, radiotherapy, avelumab, 
PF
0.000 0.000 0.000 Normal
MRU frequency, GP visit, chemotherapy, 
PF
0.333 0.268 0.399 Normal
MRU frequency, CT scan, chemotherapy, 
PF
0.115 0.093 0.138 Normal
MRU frequency, FBC, chemotherapy, PF 0.333 0.268 0.399 Normal
MRU frequency, LFT, chemotherapy, PF 0.333 0.268 0.399 Normal
MRU frequency, RFT, chemotherapy, PF 0.333 0.268 0.399 Normal
MRU frequency, TFT, chemotherapy, PF 0.000 0.000 0.000 Normal
MRU frequency, radiotherapy, chemo-
therapy, PF
0.000 0.000 0.000 Normal
Drug cost, avelumab £768.00 NA NA Not varied BNF online [46]
Drug cost, carboplatin £25.25 £25.18 £25.32 Normal eMIT [60]
Drug cost, etoposide IV £24.96 £22.16 £27.76 Normal eMIT [60]
Drug cost, etoposide oral £87.23 NA NA Not varied BNF online [46]
Drug cost, cisplatin £10.56 £10.49 £10.63 Normal eMIT [60]
AE probability, lymphopenia, avelumab 2.27% Beta JAVELIN Merkel 200 [7]
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Table 3  (continued)
Parameter Value Lower 95% 
CI
Upper 95% CI Distribution Source or justification
AE probability, anaemia, carbopl-
atin + etoposide
7.38% Beta Socinski et al. [36]
AE probability, fatigue, carboplatin + etopo-
side
3.13% Beta
AE probability, febrile neutropenia, carbo-
platin + etoposide
4.47% Beta
AE probability, hyponatraemia, carbopl-
atin + etoposide
1.12% Beta
AE probability, leukopenia, carbopl-
atin + etoposide
8.28% Beta
AE probability, nausea/vomiting, carbopl-
atin + etoposide
0.90% Beta
AE probability, neutropenia, carbopl-
atin + etoposide
46.98% Beta
AE probability, thrombocytopenia, carbopl-
atin + etoposide
10.29% Beta
AE probability, hair loss, carbopl-
atin + etoposide
34.00% Beta
AE probability, anaemia, cisplatin + etopo-
side
6.67% Beta Sun et al. [37]
AE probability, low haemoglobin, cispl-
atin + etoposide
5.33% Beta
AE probability, leukopenia, cispl-
atin + etoposide
19.33% Beta
AE probability, nausea/vomiting, cispl-
atin + etoposide
6.70% Beta
AE probability, neutropenia, cispl-
atin + etoposide
44.00% Beta
AE probability, thrombocytopenia, cispl-
atin + etoposide
7.33% Beta
AE probability, hair loss, cisplatin + etopo-
side
13.33% Beta
AE cost, anaemia £799.39 £657.09 £977.46 Normal Vouk et al. [52] and Wehler 
et al. [53]AE cost, fatigue £66.45 £53.43 £79.47 Normal
AE cost, febrile neutropenia £4543.44 £3652.94 £5433.93 Normal
AE cost, low haemoglobin £66.45 £53.43 £79.47 Normal
AE cost, hyponatraemia £66.45 £53.43 £79.47 Normal
AE cost, leukopenia £281.67 £226.46 £336.88 Normal
AE cost, lymphopenia £281.67 £226.46 £336.88 Normal
AE cost, nausea/vomiting £218.27 £181.41 £269.86 Normal
AE cost, neutropenia £281.67 £226.46 £336.88 Normal
AE cost, thrombocytopenia £286.12 £230.05 £342.20 Normal
AE cost, hair loss £0.00 £0.00 £0.00 Normal
AE disutility, anaemia − 0.090 − 0.055 − 0.133 Beta Nafees et al. [43], Ossa et al. 
[45], Tolley et al. [44] and 
assumptions validated by 
clinical expert opinion
AE disutility, fatigue − 0.073 − 0.041 − 0.114 Beta
AE disutility, febrile neutropenia − 0.090 − 0.061 − 0.124 Beta
AE disutility, low haemoglobin − 0.080 − 0.052 − 0.114 Beta
AE disutility, hyponatraemia − 0.090 − 0.062 − 0.122 Beta
AE disutility, leukopenia − 0.090 − 0.062 − 0.122 Beta
AE disutility, lymphopenia − 0.090 − 0.062 − 0.122 Beta
AE disutility, nausea/vomiting − 0.048 − 0.022 − 0.084 Beta
AE disutility, neutropenia − 0.090 − 0.062 − 0.122 Beta
AE disutility, thrombocytopenia − 0.108 − 0.089 − 0.128 Beta
AE disutility, hair loss − 0.045 − 0.021 − 0.078 Beta
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When applying the progression-based utilities, the base-
case ICERs for TE and TN patients decreased to £33,644 
and £37,494, respectively. This was due to the relatively high 
PFS health-state utility value of 0.83 (using the EQ-5D-5L 
value set) compared with the utility value for patients with 
> 100 days to death of 0.77 (using the EQ-5D-3L value set).
Applying the NDBT guidance to reflect the dosing of ave-
lumab reduced the ICERs for TE and TN patients to £32,784 
and £37,849, respectively. The NDBT for avelumab resulted 
in a lower average dose per administration, hence a lower 
cost for avelumab-treated patients.
When TN data were applied to extrapolate OS, PFS and 
ToT for TN patients until the hazard of death exceeded 
that of the extrapolation for TE patients (at approximately 
21 months), and the ToT was appropriately adjusted to 
reflect clinical expert opinion regarding discontinuation at 
2 and 5 years, the ICER increased to £48,102. This increase 
in the ICER was primarily driven by the extrapolation of 
immature ToT data.
4  Discussion
This study demonstrates that avelumab may be a cost-effec-
tive treatment option for UK TE or TN mMCC patients, 
with ICERs versus SC of £35,274 and £39,182, respectively. 
The survival benefits attributable to avelumab versus SC are 
unprecedented within the context of mMCC, therefore ave-
lumab provides a substantial improvement to the management 
of this life-threatening rare disease. A comprehensive set of 
sensitivity analyses further demonstrated the robustness of 
the base-case CEA results. The results were most sensitive 
to alternative survival extrapolations and treatment costing 
assumptions.
This study is based on a CEA considering a UK perspec-
tive, with structural features and clinical assumptions validated 
by clinical and economic experts. Data regarding the safety 
and efficacy of avelumab come from JAVELIN Merkel 200, 
the largest registrational trial conducted in mMCC to date. 
In addition to potentially prolonged survival outcomes, with 
estimated 12-month survival of 51% (95% confidence inter-
val [CI] 40–61%) and 18-month survival of 40% (95% CI 
29–50%), avelumab was shown, within the JAVELIN Merkel 
200 trial, to be a well-tolerated treatment option for mMCC 
and associated with few treatment-related AEs compared with 
conventional palliative chemotherapy regimens.
Key limitations of this study relate to the rarity of mMCC 
and, as a consequence, the adoption of the single-arm JAVE-
LIN Merkel 200 trial design. Single-arm studies are typical 
for ultra-rare diseases, particularly those with an evolving 
treatment pathway, when numerous ongoing clinical trials are 
expected to impact the future treatment pathway [57]. Naïve 
comparisons were undertaken because of the small patient 
numbers in the relevant studies. While adjusted comparisons 
were attempted (not reported in this study, but reported within 
NICE documentation), these were limited due to both sample 
sizes and the reporting of relevant patient characteristics, and 
were not greatly influential on cost-effectiveness results [55]. 
As long-term data from JAVELIN Merkel 200 become availa-
ble, the uncertainty regarding the long-term survival outcomes 
for patients treated with avelumab will reduce; however, due 
to the rarity of MCC and limited treatment options, standard 
Table 3  (continued)
Parameter Value Lower 95% 
CI
Upper 95% CI Distribution Source or justification
AE duration, anaemia 21 days 17 days 25 days Normal Assumptions validated by 
clinical expert opinionAE duration, fatigue 21 days 17 days 25 days Normal
AE duration, febrile neutropenia 4 days 3 days 5 days Normal
AE duration, low haemoglobin 21 days 17 days 25 days Normal
AE duration, hyponatraemia 2 days 2 days 2 days Normal
AE duration, leukopenia 2 days 2 days 2 days Normal
AE duration, lymphopenia 2 days 2 days 2 days Normal
AE duration, nausea/vomiting 3 days 2 days 4 days Normal
AE duration, neutropenia 2 days 2 days 2 days Normal
AE duration, thrombocytopenia 24 days 19 days 28 days Normal
AE duration, hair loss 21 days 17 days 25 days Normal
3L 3-level, 5L 5-level, AE adverse event, BNF British National Formulary, CI confidence interval, CT computed tomography, eMIT electronic 
market information tool, EoL end of life, FBC full blood count, GP general practitioner, HR hazard ratio, IV intravenous, LFT liver function 
test, LYs life-years, MRU medical resource use, NA not applicable, NHS National Health Service, NICE National Institute for Health and Care 
Excellence, OS overall survival, PF progression-free, PFS progression-free survival, PSSRU Personal Social Services Research Unit, QALYs 
quality-adjusted life-years, RDI relative dose intensity, RFT renal function test, TA technology appraisal, TE treatment-experienced, TFT thyroid 
function test, TN treatment-naïve
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methods of direct and indirect comparison will remain a limi-
tation. Extensive data collection through the generation of data 
for the SC arm and clinical expert validation was undertaken 
to mitigate this area of uncertainty within the CEA.
While data from Part A of the JAVELIN Merkel 200 trial 
(TE patients) are sufficiently mature to generate robust esti-
mates of the cost effectiveness of avelumab, data from Part 
B (TN patients) are still maturing. The CEA results for TN 
patients in this study provide indicative cost-effectiveness 
estimates for avelumab, with extended follow-up needed 
from Part B of the JAVELIN Merkel 200 trial to establish 
the full benefits of avelumab in a first-line setting. However, 
these early CEA results indicate avelumab is likely to be 
a cost-effective treatment option for TN patients based on 
clinically validated CEA inputs and assumptions based on 
the mature TE data.
5  Conclusions
Our study exemplifies avelumab as a promising, innovative 
and cost-effective treatment for a small, underserved patient 
population with limited, and unlicensed, treatment options 
associated with a poor benefit-to-risk ratio. In May 2018, 
the availability of avelumab extended to include all UK TE 
and TN patients with mMCC in England and Scotland [18, 
58]. Avelumab therefore represents a step change in therapy 
to these patients, and a cost-effective use of NHS resources 
with a limited budget impact based on an incident population 
of approximately 100 UK mMCC patients per year.
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